Inmed Pharmaceuticals Inc. (INM) has released an update.
InMed Pharmaceuticals Inc. has strengthened its commitment to Alzheimer’s treatment research by appointing Dr. David G. Morgan, a distinguished Alzheimer’s expert, to its Scientific Advisory Board. Dr. Morgan’s extensive experience in neurodegenerative disease research will be pivotal for the advancement of InMed’s INM-901 program, which targets the treatment of Alzheimer’s disease. The company, a leader in cannabinoid-based pharmaceuticals, is poised to benefit from Dr. Morgan’s expertise in the next stages of drug development.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.
